Brickell Biotech, Inc. (BBI) Financial Analysis & Valuation | Quarter Chart
Brickell Biotech, Inc. (BBI)
BBIPrice: $2.35
Fair Value: 🔒
🔒score
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase II... more
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of vario... more
Description
Shares
| Market Cap | $7.08M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Robert Brown |
| IPO Date | 1993-03-10 | CAGR | -0.05% |
| Employees | 16 | Website | www.brickellbio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
BBI chart loading...
Fundamentals
Technicals
| Enterprise Value | $-14.11M | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 0.7 | P/B Ratio | 0.56 |
| P/CF Ratio | -1.27 | P/FCF Ratio | -1.29 |
| EPS | $-0.42 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 1277.74% | Gross Margin | 1% |
| Operating Margin | -0.79% | Profit Margin | -0.71% |
| ROE | -0.67% | ROA | -0.49% |
| ROCE | -0.64% | Current Ratio | 6.98 |
| Quick Ratio | 6.98 | Cash Ratio | 6.56 |
| Debt/Equity | — | Interest Coverage | -1272 |
| Altman Z Score | -7.34 | Piotroski Score | 4 |